A 9-amino-acid peptide originally isolated from rabbit brain during slow-wave (delta) sleep. Promotes deep sleep, modulates stress responses, and has analgesic and anticonvulsant properties. One of the earliest neuropeptides studied for sleep regulation.
DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide first isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced slow-wave sleep. Its sequence (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is highly conserved across mammalian species.
Despite its name, DSIP does not simply 'knock you out' like a sleeping pill. Instead, it modulates the sleep-wake architecture — promoting the transition into delta (slow-wave) sleep, the deepest and most restorative phase. It also has stress-modulating, analgesic, and anticonvulsant properties, suggesting it acts as a broad neuromodulator rather than a specific sleep switch.
DSIP's mechanism is multifactorial and not fully elucidated. Evidence suggests it enhances GABAergic inhibition in sleep-promoting nuclei (VLPO), modulates serotonergic signaling in the raphe nuclei (which regulate sleep-wake transitions), and may directly influence the thalamocortical circuits responsible for generating delta wave oscillations during deep NREM sleep.
| Pathway | Effect | Significance |
|---|---|---|
| Delta sleep promotion | Enhances slow-wave (delta) sleep duration and depth | Increases the most restorative sleep phase |
| Stress modulation | Normalizes cortisol and ACTH rhythms under chronic stress | Reduces stress-induced insomnia and anxiety |
| Analgesic effects | Modulates endogenous opioid system activity | Reduces pain perception in animal and human studies |
| Anticonvulsant | Reduces glutamatergic excitability | Raises seizure threshold in animal models |
| Circadian modulation | Influences melatonin and cortisol circadian rhythms | May help normalize disrupted sleep-wake cycles |
| Study | Design | Findings | Level |
|---|---|---|---|
| Sleep architecture | Human pilot studies | Increased delta sleep percentage and reduced sleep latency in insomnia patients | Level II-III |
| Chronic pain | Clinical pilot | Improved sleep quality and reduced pain scores in chronic pain patients | Level II-III |
| Opiate withdrawal | Clinical studies | Reduced withdrawal symptoms and improved sleep in opiate-dependent patients | Level II-III |
| Stress reduction | Human studies | Normalized cortisol rhythms and reduced stress markers in chronically stressed subjects | Level II-III |
| Narcolepsy | Case series | Some improvement in daytime sleepiness and sleep architecture | Level III-IV |
Generally well-tolerated: No significant adverse effects reported in clinical studies at standard doses.
No morning sedation: Unlike many sleep medications, DSIP promotes natural sleep architecture without next-day drowsiness.
No dependence: No evidence of tolerance or withdrawal with repeated use.
Limited data: Most studies are small. Large-scale safety data is lacking.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved. Not reviewed. |
| International | Available as a research peptide |
| Research status | Despite decades of study, DSIP's exact receptor remains unidentified, limiting drug development |